This integrated Annual Review discusses many dimensions of our performance — financial, social and environmental — in one review. It demonstrates the integral relationship between our responsibilities as an enterprise and our core business strategies and their execution. We produce this review to give all of our stakeholders an overall picture of how we are doing and the progress we are making.
This review covers Pfizer's worldwide business and provides information on our activities for the year ending on December 31, 2015. This review describes key dimensions of both financial and non-financial performance. It also describes critical challenges in society — from expanding access to health care to our environmental impact — and our strategies for managing them.
The content of this report is based on two key factors — the importance to stakeholders and the potential to influence business strategy. Our Corporate Responsibility team works with colleagues across the organization and engages with external stakeholders to help identify the critical issues we need to focus on in order to meet our commercial goals and society's expectations. These include the following specific, non-financial corporate responsibility material issues:
We greatly value our stakeholders' perspectives, and all Pfizer units globally and locally engage with stakeholders on relevant issues throughout the year. Additionally, in 2015, we convened a small group of key independent socially responsible investors (SRIs) to gain additional perspectives on our corporate responsibility performance and on reporting expectations. We have used their valuable feedback to help shape the content of this report. We continue to explore new ways of engaging with a broad range of stakeholders to better understand the evolving reporting environment and determine how key non-financial indicators are impacting our financial performance.
This review was developed by a core group of Pfizer colleagues representing each business unit and other key functions. The core group is managed by Pfizer's Corporate Affairs department, whose leader is a member of the Executive Leadership Team and reports directly to the CEO. Pfizer's commitment to society is embedded in our business strategy and vision, and our business units and functional groups share the commitment to integrate such values in our daily work. The Corporate Responsibility team sets the strategic direction for meeting our commitment to society and supports the integration and implementation of programs and non-financial reporting throughout the company. The team is also responsible for Pfizer's flagship global health social investment programs and providing annual updates to Pfizer's Board of Directors on progress in achieving corporate responsibility goals.
Pfizer continues to evaluate our approach to non-financial reporting, including adherence to several existing, globally recognized external frameworks. These include the Global Reporting Initiative (GRI), the Sustainability Accounting Standards Board (SASB) and the International Integrated Reporting Council (IIRC). We have relied on elements of each framework in developing this year's annual review while adhering to none in its entirety. Based on feedback we received in 2015 from a few key stakeholders, we decided to include a GRI Reference Table in this Annual Review as a reference tool to help readers more readily locate relevant information across Pfizer's web-based resources.
We also take into account elements of other Environment, Social and Governance (ESG) indices and sustainability indicators, in particular the Access to Medicines Index and the UN Global Goals (also known as the Sustainable Development Goals).